Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

CRRAB II > PBL pharmacology > Flashcards

PBL pharmacology Flashcards

1
Q

Fluoroquinolones (Ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, moxifloxacin, gemifloxacin, enoxacin) MOA

A

Inhibit prokaryotic enzymes topo II (DNA gyrase) and topo IV. Bactericidal. Do NOT take with antacids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fluoroquinolone clinical use

A

G- rods of urinary and GI tracts and some G+ organisms. Pyelonephritis (1st line treatment).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Fluoroquinolone toxicity

A

GI upset, superinfections, skin rashes, HA, dizziness. Can cause leg cramps and myalgias. Contraindicated in pregnant/nursing mothers and children under 18. Can damage tendons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fluoroquinolone mechanism of resistance

A

Chromosome encoded mutation in DNA gyrase, plasmid-mediated resistance, efflux pumps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Trimethoprim MOA

A

Inhibits bacterial dihydrofolotate reductase. Bacteriostatic. Use with sulfonamide.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Trimethoprim clinical use

A

In combo with sulfonamides, causing sequential block of folate synthesis. Combination used for UTIs (pyelonephritis only if susceptible), pneumonia treatment and prophylaxis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Trimethoprim toxicity

A

Megaloblastic anemia, leukopenia, granulocytopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Sulfonamides (sulfamethoxazole, sulfisoxazole, sulfadiazine) MOA

A

Inhibits folate syntheses. PABA antimetabolites inhibit dihydropteroate synthase. Bacteriostatic. Bacteriocidal when used with trimethoprim.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sulfonamide clinical use

A

G+ and G-. UTI treatment with trimethoprim or just SMX with simple UTI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sulfonamide toxicity

A

Hypersensitivity reactions, hemolysis if G6PD deficient, nephrotoxicity, photosensitivity, kernicterus in infants.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sulfonamide mechanism of resistance

A

Altered enzyme, decreased uptake or increased PABA synthesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ceftriaxone MOA

A

3rd generation cephalosporin. Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. Inhibiting cell wall biosynthesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ceftriaxone clinical use

A

Can be given to treat pyelonephritis if the fluoroquinolone resistance of E. Coli is greater than 10%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Aminoglycoside (Gentamicin, neomycin, amikacin, tobramycin, streptomycin) MOA

A

Bactericidal. Irreversible inhibition of complex by binding 30S subunit. Can cause misreading of mRNA. Block translocation. Require O2 for uptake. Ineffective against anaerobes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aminoglycoside clinical use

A

Treat pyelonephritis if fluoroquinolone resistance of E coli greater than 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

First line empiric treatment for uncomplicated cystitis

A

Nitrofurantoin or Trimethoprim/Sulfamethoxazole or fosfomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fosfomycin MOA

A

Phosphoric acid derivative, inhibits bacterial wall synthesis (bactericidal) by inactivating the enzyme, pyruvyl transferase, which is critical in the synthesis of cell walls by bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Fosfomycin clinical use

A

Cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Nitrofurantoin MOA

A

Reduced by bacterial flavoproteins to reactive intermediates that inactivate or alter bacterial ribosomal proteins leading to inhibition of protein synthesis, aerobic energy metabolism, DNA, RNA, and cell wall synthesis. Nitrofurantoin is bactericidal in urine at therapeutic doses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Nitrofurantoin clinical use

A

UTI treatment (not pyelonephritis) and acute cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

First line treatments for pyelonephritis

A

Fluoroquinolones unless resistance greater than 10% (than use ceftriaxone or aminoglycoside). Can use Trimethoprim-Sulfamethoxazole if susceptible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Rapid acting insulin (names, onset, time to peak effect, duration of action)

A
  • -Can be taken immediately before a meal
  • -Onset: 10-30 min
  • -Time to peak effect: 30-60 min
  • -Duration of action: 3-5 hours
  • -Names: Aspart, lispro, glulisine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Regular (short) acting insulin

A
  • -Onset: 30-60 min (U-100), 30 min (U-500)
  • -Time to peak effect: 1.5-2 hrs (U-100), 4-8 hrs (U-500)
  • -Duration of action: 5-12 hrs (U-100), 14-15 hrs (U-500)
  • -Names: Humulin R and Novolin R (U-100), Humulin R (U-500)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

NPH (intermediate) insulin

A
  • -Onset: 1-2 hours
  • -Time to peak effect: 4-8 hours
  • -Duration of action: 10-20 hours
  • -Names: Humulin N, Novolin N (insulin isophane suspension)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Glargine insulin
- -Onset: 1-2 hrs - -Time to peak effect: No peak, max 4-6 hours though - -Duration of action: 24 hrs - -Names: lantus
26
Azathioprine MOA (and use)
- -Imidazolyl derivative of mercaptopurine. - -Metabolites incorporated into replicating DNA and halt replication--> block pathway for purine synthesis. - -Immunosuppressive and toxic effects. - -6-thioguanine nucleotides mediate. - -Sometimes used to treat HSP
27
Cyclophosphamide MOA (and use)
- -Alkylating agent - -Prevents cell division by cross-linking DNA strands and decreases DNA synthesis. - -CCNS agent - -Immunosuppressant. - -Prodrug metabolized in liver - -HSP treatment when crescents present
28
Mycophenolate mofetil MOA (and use)
- -Cytostatic effect on T and B lymphocytes - -Inhibits inosine monophosphate dehydrogenase (enzyme that controls rate of synthesis of GMP in de novo purine pathway). - -Inhibits de novo guanine synthesis - -Sometimes used for severe HSP
29
Corticosteroid (Prednisone) MOA
- -Metabolic, catabolic, anti-inflammatory, immunosuppressive effects - -Mediated by interactions w/glucocorticoid response elements (GRE), inhibition of phospholipase A2, inhibition of transcription factors such as NF-kB.
30
Opioid (Morphine, fentanyl, codeine, loperamide, methadone, meperidine, dextromethorphan, diphenoxylate, pentazocine) MOA
- -Acts as agonists at opioid receptors (u=morphine, delta= enkephalin, k=dynorphin) to modulate synaptic transmission - --Opens K+ channels, close Ca++ channels-->DECREASE synaptic transmission. - -Inhibit release of ACh, NE, 5-HT, glutamate, substance P
31
Rifamycins (Rifampin, Rifabutin) MOA
Inhibits DNA-dependent RNA polymerase. Bactericidal animycobacterial agents, IC and EC activity
32
4 R's of rifampin
RNA polymerase inhibitor Ramps up microsomal cytochrome P-450 Red/orange body fluids Rapid resistance if used alone
33
What is different about rifampin vs rifabutin
Rifampin ramps up P-450 but rifabutin doesn't
34
Rifamycins toxicity
--Minor hepatotoxicty, drug interactions, red/orange body fluids (non-hazardous side effects)
35
Which Rifamycin drug is preferred when pt is HIV+
Rifabutin because it doesn't have as much cytochrome P-450 activity.
36
Mechanism of resistance of Rifamycins
Mutations reduce drug binding to RNA polymerase.
37
Isoniazid MOA
Decreases synthesis of myocolic acids. Bacterial catalase-perioxidase needed to convert Inh to active metabolite. I
38
Isoniazid use
Mycobacterium TB. Only agent used as solo prophylaxis against TB.
39
Isoniazid toxicity
Neurotoxicity, hepatoxicity. Pyridoxine (Vit B6) can prevent neurotoxicity.
40
Isoniazid mechanism of resistance
Mutations leading to underexpression of KatG (needed to convert prodrug to active drug)
41
Pyrazinamide
Mechanism uncertain. Prodrug converted to active compound pyrazinoic acid. Acts intracellularly. Toxicity includes hyperuricemia and hepatotoxicity.
42
Ethambutol Mechanism
Decreases carbohydrate polymerization of mycobacterium cell wall by blocking arabinosyltransferase.
43
Ethambutol use
Mycobacterium tubuerculosis
44
Rifamycin use
Mycobacterium tuberculosis. Delay resistance to dapsone when used for leprosy. Meningococcal prophylaxis in kids w/HIB.
45
Ethambutol toxicity
Optic neuropathy (leading to red-green color blindness)
46
Pyridoxine (Vitamin B6) MOA
Precursor to pyridoxal. Functions in metabolism of proteins, carbs, fats. Also aids in release of liver and muscle stored glycogen and synthesis of GABA and heme.
47
Amphotericin B and nystatin MOA
Binds ergosterol and forms membrane pores that allows leakage of electrolytes. Fungicidal.
48
Amphotericin B use
Serious, systemic mycoses. Cryptococcus, blastomyces, coccidioides, histoplasma, candida, mucor. Intrathecally for fungal meningitis. Supplement K+ and Mg++ because of altered renal tubule permeability.
49
Amphotericin B toxicity
Fever/chills, hypotension, nephrotoxicity, arrhythmias, anemia, IV plebitis. Hydration will decrease nephrotoxicity. Liposomal amphotericin decreases toxicity
50
Nystatin use
Only topical. Too toxic for systemic use. "Swish and swallow for thrush, topical for diaper rash or vaginal candidiasis
51
Flucytosine MOA
Inhibits DNA and RNA biosynthesis by conversion of 5-FU by cytosine deaminase
52
Clinical use of flucytosine
Systemic fungal infections (esp. meningitis caused by cryptococcus). Used in combo w/amphotericin B
53
Flucytosine toxicity
Bone marrow suppression
54
Azoles (6 names)
Clotrimazole, fluconazole, itraconazole, ketoconazole, miconazole, voriconazole
55
-Azoles MOA
Inhibit fungal sterol (erggosterol) synthesis by inhibiting cytochrome P-450 enzyme that converts lanosterol to ergosterol
56
-Azoles clinical use
Local and less serious systemic mycoses. Fluconazole for chronic suppression of cryptococcal meningitis in AIDS patients and all types of candidal infections. Itraonazole for blastomycoses, coccidioides, histoplasma. Clotrimazole and miconazole for topical infections
57
-Azoles toxicity
--Testosterone synthesis inhibition (gynecomastia), liver disfunction (altered cytochrome P-450.
58
Protease inhibitors MOA
- -Prevent maturation of new viruses by inhibiting protease, which is needed to cleave polypeptide products of HIV mRNA into functional parts - -Does nothing for cells that are already infected because it doesn't inhibit provirus
59
Protease inhibitor names
- -END IN -NAVIR | - -Atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir
60
Protease inhibitor toxicty
Hyperglycemia, GI intolerance, lipodystrophy, nephropathy, hematuria (indinavir). Rifampin is contraindicated with protease inhibitors because it can decrease drug concentration.
61
Integrase inhibitors (drug name)
Raltegravir
62
Raltegravir MOA
Inhibits HIV genome integration into host cell chromosome | --Reversibly inhibits HIV integrase
63
Raltegravir toxicity
Increases creatine kinase
64
Ritonavir boosting
Can be used at low doses to "boost" other drug concentrations by inhibiting P-450 and CPYP3A4
65
Fusion inhibitors (2 drugs)
Enfuvirtide and maraviroc
66
Enfuvirtide MOA
Binds gp41 and inhibits viral entry
67
Enfuvirtide toxicity
Skin reactions at injection sites (this makes it not a first line drug choice)
68
Maraviroc MOA
Binds CCR-5 on surface of T cells/monocytes. Inhibits interactions w/gp120. --Only useful is strains that have single CCR-5 tropism
69
Maraviroc toxicity
Pyrexia, rash, postural dizziness
70
NRTIs (Nucleoside reverse transcriptase inhibitors) (Drug names)
- -Abacavir - -Didanosine - -Emtricitabine - -Lamivudine - -Stavudine - -Tenofovir - Zidovudine
71
NRTI MOA
Competitively inhibit nucleotide binding to reverse transcriptase and terminate DNA change. Tenofovir nucleotide and the rest are nucleosides (need to be phosphorylated to be active).
72
What drug is used as general prophylaxis and during pregnancy to decrease risk of fetal transmission?
Zidovidine (AZT or ZDV)
73
NRTI toxicity
- -Bone marrow suppression (can reverse w/G-CSF) - -Peripheral neuropathy - -Lactic acidosis (nucleosides) - -Granulocytopenia and anemia (AZT) - -Pancreatitis (Didanosine)
74
NNRTI drug names
- -Delavirdine - -Efavirenz - -Nevirapine
75
NNRTI MOA
Bind to reverse transcriptase at different site from NRTIs. Don't require phosphorylation to be active or compete with nucleosides. Allosteric inhibitors.
76
NNRTI toxicity
- -Rash - -Hepatotoxicity - -Vivid dreams and CNS symptoms (common with efavirenz) - -Delavirdine and efavirenz contraindicated in pregnancy.
77
Albuterol and pirbuterol class and use
- -Short-acting B2 agonist | - -Acute exacerbations of asthma and COPD (obstructive airway disease)
78
Albuterol and pirbuterol MOA
Stimulates B2 receptors ---> Relaxes bronchial smooth muscle --Acts on AC (ATP--> cAMP)
79
Pharmacokinetics of Albuterol and pirbuterol
- -Max. effect in 15 min - -Lasts 3-4 hours - -Liver metabolism - -Urine excretion (30% unchanged)
80
B2 agonist side effects
Tachycardia, skeletal muscle tremors and cramping, HA, palpitations, prolongation of QT interval, insomnia, hypokalemia, increases in serum glucose, tolerance with long-term use
81
Albuterol and pirbuterol delivery device
- -Metered dose inhalers | - -Nebulizer
82
Salmeterol, formoterol, aformoterol class and use
- -Long-acting B2 agonists - -Prevention of bronchospasm in COPD and asthma - -Not usually monotherapy
83
Salmeterol, formoterol, aformoterol MOA
Stimulates B2 receptors--> relaxes bronchial smooth muscle. Long-acting agents
84
Salmeterol, formoterol, aformoterol pharmacokinetics
- -12+ hr duration of action - -High lipid solubility. - -Enter smooth muscle cell in high concentration - -Interact w/inhaled corticosteroids
85
Salmeterol delivery device
Dry-powder inhaler
86
Formoterol delivery device
- -Dry-powder inhaler | - -Nebulizer
87
Aformoterol delivery device
Nebulizer
88
Ipratropium delivery device
- -Nebulizer | - -Metered dose inhaler
89
Ipratropium MOA
Competitively blocks muscarinic acetylcoline receptors--> prevents bronchoconstriction
90
Ipratropium use
Asthma and COPD
91
Ipratropium and Tiotropium side effects
- -Dry mouth - -Pharyngeal irritation - -Urinary retention - -Increases in intraocular pressure
92
Tiotropium MOA
Blocks muscarinic receptors--> reduces smooth muscle contraction and mucus secretion
93
Tiotropium class
Long-acting muscarinic antagonists
94
Tiotropium delivery device
Dry-powder inhaler
95
Inhaled corticosteroids (Fluticasone, Budesonide, Triamcinolone, Beclomethasone, Flunisolide) MOA
- -Inhibit PLA2--> decreases amino acid synthesis and its inflammatory metabolites. - -Inhibits NF-kB--> suppresses TNF-a and other inflammatory agents. Inhibits synthesis of virtually all cytokines--> reduces bronchial hyper-reactivity
96
Fluticasone and budesonide delivery device
Dry-powder inhaler | Nebulizer
97
Inhaled corticosteroids uses
1st line therapy for chronic asthma w/long acting B2 agonists. Also used for other obstructive lung diseases
98
Inhaled corticosteroid side effects
- -Oral candidiasis (most common) - -Cushingoid changes - -Dysphonia - -Osteoporosis - -Pneumonia - -Side effects are all less common than in systemic forms
99
Systemic corticosteroids (Methylprednisolone, prednisone, dexamethasone, betamethasone) MOA
- -Transcriptionally regulate/inactivate synthesis of PLA2--> inhibit synthesis of inflammatory agents - -Inhibit NF-kB. Suppress both B and T cell function by decreasing transcription of many cytokines
100
Systemic corticosteroid delivery system
- -IV | - -Orally
101
Systemic corticosteroid side effects
- Iatrogenic Cushing Syndrome (HTN, weight gain, moon facies, osteoporosis, hyperglycemia, amenorrhea, Buffalo hump, immunosuppression), - -Adrenocortical atrophy - -Peptic ulcers - -Steroid diabetes - -Steroid psychosis. - -Adrenal insufficiency when stopped abruptly after chronic use.

CRRAB II (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions